<DOC>
	<DOCNO>NCT01199718</DOCNO>
	<brief_summary>This Phase 1 study oral CX-4945 design test safety , tolerability , high safe dose level CK2 inhibitor patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>Study CX-4945 Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Elevated CK2 activity associate malignant transformation aggressive tumor growth . Over expression CK2 document multiple type cancer , include multiple myeloma , inhibition CK2 represent potential therapeutic strategy target specific molecular defect perpetuate many cancer . CX-4945 demonstrate potent inhibition CK2 enzymatic activity . This study evaluate safety , pharmacokinetics , pharmacodynamic effect CX-4945 administer patient multiple myeloma .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Males female least 18 year age Confirmed relapsed refractory multiple myeloma least two prior line therapy . Measureable disease . Karnofsky Performance Status least 60 % Adequate liver renal function hematology laboratory value Female patient childbearing potential must negative pregnancy test . Signed informed consent . Treatment systemic cancer therapy within 21 day screen . Major surgery within 4 week minor surgery within 2 week start study drug . Grade 3 sensory neuropathy motor neuropathy pain Concurrent severe uncontrolled medical disease . Active systemic fungal , bacterial , and/or viral infection . Difficulty swallowing , active malabsorption syndrome . Gastrointestinal disease include Crohn 's disease hemorrhagic coloproctitis . History gastric small bowel surgery . Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Multiple myeloma</keyword>
	<keyword>Plasmacytoma</keyword>
</DOC>